Survival in metastatic renal cell carcinoma. Medical search. Frequent questions

A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study. (urologytimes.com)
The results support an ongoing phase III study of the approach in which patients with metastatic clear-cell RCC are being randomized to personalized immunotherapy plus sunitinib or sunitinib alone, with overall survival as the primary endpoint, said first author Asim Amin, MD, PhD. (urologytimes.com)
For the overall study population, median progression-free survival was 11.2 months and the final median overall survival was 30.2 months. (urologytimes.com)
Fifty-two percent had overall survival greater than 30 months. (urologytimes.com)
The estimated median overall survival is 39.5 months for intermediate- and 9.1 months for poor-risk subjects. (urologytimes.com)
By comparison, in a pivotal trial, treatment with sunitinib yielded a median overall survival of 20.7 months for intermediate-risk and 5.3 months for poor-risk subjects. (urologytimes.com)
A new study from a team based in Italy demonstrates that a higher free triiodothyronine to free thyroxine (fT3/fT4) ratio is associated with prolonged progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC). (medpagetoday.com)
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. (bvsalud.org)
No significant differences in progression-free survival (HR 0.74, 95 % CI 0.48-1.1, p = 0.14) or overall survival (HR 0.66, 95 % CI 0.39-1.09, p = 0.11) were observed between patients achieving partial response versus stable disease . (bvsalud.org)
In addition, progression free survival (PFS) and overall survival (OS) were analysed. (urotoday.com)
In short, patients randomized to the combination had significantly improved overall survival rates compared with those randomized to sunitinib. (aacr.org)
In addition, at that time, it was not possible to estimate the median overall survival among those receiving the immunotherapy combination, whereas it was estimated to be 25.9 months among those who received sunitinib. (aacr.org)
In terms of survival analysis, patients with PD-1 expression either in the primary or metastasis had a shorter overall survival (OS) (HR: 1.59, 95% CI 1.08-2.36, p = 0.02). (biomedcentral.com)
Median overall survival (OS) in the overall cohort was 18.0 months (95% CI 6.9-22.0). (simulations-plus.com)
Longer overall survival (28.7 months, 95% CI=24.5-38.3) probably is an effect of patient characteristics and follow-up therapies. (iiarjournals.org)
Secondary endpoints included overall survival and objective response rate. (businesswire.com)
Median overall survival had not been reached in any group. (ascopost.com)
Toxicity, ORR and overall survival (OS) were retrospectively evaluated. (bmj.com)
Primary endpoints were overall survival and progression-free survival in the intention-to-treat population. (urotoday.com)
In the double-blind study, which was conducted in Asia, the median overall survival (OS) was 5.32 months with Opdivo versus 4.14 months in the placebo arm. (curetoday.com)
Variables and outcomes analyzed in each group included the percent of patients with metastatic disease at presentation, lymph node involvement, Eastern Cooperative Oncology Group score, response to immunotherapy, and median and overall survival using Kaplan-Meier curves. (nih.gov)
1 , 2 In one trial, a significant improvement in progression-free survival (PFS) was seen with sunitinib over interferon-alfa (11 vs 5 months), 1 with a borderline statistically significant benefit in overall survival despite robust crossover. (jnccn.org)
The study met both its primary and key secondary endpoints, demonstrating superior overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) for the dual immunotherapy plus chemotherapy combination versus chemotherapy alone. (bms.com)
The updated one-year overall survival data from CheckMate -9LA, along with three-year results from our CheckMate -227 trial, further reinforce the clinical value of Opdivo plus Yervoy -based combinations, the first-ever dual immunotherapy options for the treatment of first-line non-small cell lung cancer. (bms.com)
Adding perifosine to capecitabine does not prolong overall survival in refractory metastatic colorectal cancer, according to results of phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting. (cancertherapyadvisor.com)
Median overall survival was 37.2 months. (edu.au)
Conclusion: In this retrospective review of the 2/1 sunitinib schedule, time on treatment with clinical benefit exceeded the overall survival times seen in the phase III trials utilizing the 4/2 schedule. (edu.au)
Overall survival also exceeded that seen in these trials. (edu.au)
Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma. (cdc.gov)
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. (medscape.com)
[ 9 ] Experience with immune checkpoint inhibitors has shown that the overall survival (OS) benefit with CIT is often not fully reflected in RECIST v1.1-based progression-free survival (PFS) or overall response rate (ORR). (medscape.com)
The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. (lu.se)
New Standard of Care in Cervical Cancer The combination resulted in significant improvements in both progression-free and overall survival compared with chemotherapy (with or without bevacizumab) alone. (medscape.com)

When analyzed by baseline Heng risk status, the median progression-free survival was 19.4 months for intermediate-risk patients and 5.8 months for subjects with poor-risk features at baseline. (urologytimes.com)
Significant differences in progression-free survival (HR 0.13, 95 % CI 0.09-0.22, p survival (HR 0.33, 95 % CI 0.23-0.48, p patients achieving stable disease compared to those with progressive disease and who were not evaluable. (bvsalud.org)
There was no statistically significant difference between the arms for progression-free survival. (aacr.org)
In addition, results presented earlier this week at the AACR Annual Meeting 2018 , which were simultaneously published in The New England Journal of Medicine and highlighted on this blog , showed that a combination of ipilimumab and nivolumab significantly improved the overall response rate and median progression-free survival among certain patients with non-small cell lung carcinoma, compared with standard-of-care chemotherapy. (aacr.org)
Results: Progression-free survival (10.2 months, 95% CI=8.6-12.6) and overall response rate (27.2%) outcomes match the results from the phase III trials AVOREN and CALGB 90206. (iiarjournals.org)
All these treatment options are approximately comparable in terms of progression-free survival (PFS) and can be used under the premise of favorable to moderate prognosis according to the Memorial Sloan-Kettering Cancer Center (MKSCC)-criteria for first-line therapy of advanced or metastatic RCC. (iiarjournals.org)
With our partner Exelixis, we are very pleased that CABOSUN's primary endpoint of a statistically significant improvement of progression-free survival has been confirmed by the independent radiology review committee in patients with previously untreated advanced intermediate- or poor-risk RCC. (businesswire.com)
To determine if ado-trastuzumab emtansine (T-DM1) shows better progression-free survival (PFS) when compared to docetaxel plus trastuzumab (TH) in recurrent and/or metastatic (R/M) HER2-positive salivary gland cancer (SGC) patients who have not previously received HER2 therapy for unresectable or recurrent and/or metastatic disease, as determined by local assessment. (karmanos.org)
The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months. (news-medical.net)
Of the 4 patients who underwent targeted therapy, the median follow up was 33 months with a median progression free survival of 16 months. (scirp.org)
In the current study, we aimed to investigate the effects of concurrent PPIs on palbociclib and ribociclib efficacy in terms of progression free survival in metastatic breast cancer (mBC) patients. (researchsquare.com)
The primary endpoint of the study was OS, and secondary endpoints focused on progression-free survival (PFS) and objective response rate (ORR). (curetoday.com)
The primary endpoint of the study is OS, and secondary endpoints include progression-free survival (PFS) and objective response rate (ORR) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 modified for mesothelioma, safety and quality of life. (merck.com)
imRECIST progression-free survival (PFS) did not count initial PD as an event if the subsequent scan showed disease control. (medscape.com)

The role of cytoreductive nephrectomy (CN) in treatment of locally advanced or metastatic renal cell carcinoma (mRCC) in the era of targeted therapies (TT) is still not clearly defined. (muni.cz)
Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly diagnosed renal cell cancers. (mdpi.com)
In metastatic renal cell carcinoma (mRCC), survival benefit associated with objective response rates of 16-20 % with high- dose interleukin-2 (HDIL-2) is well established and discussed. (bvsalud.org)
Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), inter-feron-alfa (IFN) as single agents or in combina-tion, with or without chemotherapy. (thieme-connect.de)
Histopathological examination of these immune check points in metastatic lesions of mRCC should be noticed, and its accurate diagnosis may be one of the effective ways to realize the individualized treatment. (biomedcentral.com)
Among all RCC patients, nearly 20-30% of them were initially diagnosed as metastatic RCC (mRCC), and 20-40% of patients with localized disease will eventually develop metastatic disease after surgery [ 3 ]. (biomedcentral.com)
Objectives: Sarcomatoid metastatic renal cell carcinoma (mRCC) represents an aggressive subset of disease, and a definitive therapeutic strategy is lacking. (simulations-plus.com)
Conclusions: Compared with previous series and prospective trials assessing patients with sarcomatoid mRCC, the observed survival was prolonged. (simulations-plus.com)
Aim: Sunitinib is a first-line treatment option for metastatic renal cell carcinoma (mRCC) funded by the Australian Pharmaceutical Benefits Scheme. (edu.au)

Increasingly, renal cell cancers are diagnosed at an earlier stage, and nephron-sparing surgery, thermal ablation, and surveillance are gaining acceptance as a treatment of choice for smaller tumors. (medscape.com)
PD-1, PD-L1 and PD-L2 were differentially expressed between primary and metastatic tumors. (biomedcentral.com)
Among them, the heterogeneity of the tumor may play an important role, especially the heterogeneity between the primary and metastatic tumors. (biomedcentral.com)
The majority of clear cell RCC tumors have lower than normal levels of a protein called von Hippel-Lindau, which leads to higher levels of MET, AXL and VEGF. (businesswire.com)
Renal masses are a biologically heterogeneous group of tumors, ranging from benign masses, to indolent cancers that behave in a benign fashion, and finally, extremely aggressive and deadly cancers. (ahrq.gov)
1,2 The true incidence of renal masses (including benign lesions) is unknown, but benign lesions comprise approximately 20% of surgically resected tumors. (ahrq.gov)
No test is effective at screening for renal cell carcinoma, and most tumors are detected incidentally during an evaluation for unrelated or non-specific complaints. (ahrq.gov)
MSCT can detect, characterize, and stage renal tumors in one fast, high-resolution examination, assuming that a tailored multiphasic protocol is followed. (diagnosticimaging.com)
Upper pole tumors with direct extension into the adrenal gland predict significantly worse survival than similarly staged tumors with fat invasion and they have a prognosis similar to that of stage pT4 disease. (nih.gov)
Immune-related response criteria (irRC) were developed based on experience with ipilimumab (anti-cytotoxic T-cell lymphocyte-4) in melanoma to better capture the response to CIT per changes in tumor biology and the long-termeffects of CITon solid tumors and to enable additional adaptations as the field evolved. (medscape.com)
RCC, an adenocarcinoma, accounts for 90 to 95% of primary malignant renal tumors. (msdmanuals.com)
Patient summary We examined the literature to determine the most effective treatments for advanced kidney cancer patients whose tumors are not of the clear cell subtype. (lu.se)
Some localized melanomas may result from azathioprine, which acts synergistically with ultraviolet radiation, while T-cell depleting induction therapies may promote late stage tumors. (cdc.gov)

The hope is that those dendritic cells will then express the patient's own tumor antigens to the T cells. (urologytimes.com)
Simple Summary: The treatment of metastatic renal cell carcinoma is traditionally initiated with the removal of the diseased kidney with the tumor in many patients. (muni.cz)
Liver metastasis, high-grade tumor, absence of CN, non-clear cell histology, and MSKCC (Memorial Sloan-Kettering Cancer Center) poor prognosis status were associated with adverse treatment outcomes. (muni.cz)
Other genetically linked conditions also increase the risk of RCC, including hereditary papillary renal carcinoma, hereditary leiomyomatosis, Birt-Hogg-Dube syndrome, hyperparathyroidism-jaw tumor syndrome, familial papillary thyroid carcinoma, von Hippel-Lindau disease and sickle cell disease. (wikipedia.org)
Genetic studies of the families at high risk for developing renal cancer led to the cloning of genes whose alteration results in tumor formation. (medscape.com)
and cell differentiation ( SOX2 and TGFB3 ) as well as immunohistochemical assay for VEGFA, TP53, Bcl2, TGFB1, and Ki67 protein expression have been performed in 85 FFPE RCC tumor specimens. (hindawi.com)
Ablation involves destroying the tumor cells. (healthline.com)
However, immune checkpoints may express differently between primary and metastatic tumor. (biomedcentral.com)
The key procedure of anti-tumor respond is the activation of T cell and tumor cells can inhibit this process through binding its immune checkpoints to receptors expressed on T-cell, thus leading to immune escape. (biomedcentral.com)
Mutation of the VHL tumor suppressor gene is observed in up to 80% in clear cell kidney cancers, leading to increased rates of VEGF secretion in RCC ( 11 ), thus being a promising candidate for VEGF-targeted therapy. (iiarjournals.org)
Renal cell cancer is the most frequently encountered malignant tumor in the kidney. (diagnosticimaging.com)
Prognosis and outcome of renal cell carcinoma are influenced by tumor stage and grade at the time of diagnosis. (diagnosticimaging.com)
The therapeutic approach for renal cell carcinoma is guided by the probability of cure, which is related directly to the stage or degree of tumor dissemination. (medscape.com)
Dendritic cell vaccinations were done s.c. every 2 weeks for four times and repeated monthly until tumor progression. (aacrjournals.org)
These results suggest that the level of vena caval involvement by tumor thrombus in patients with renal cell carcinoma has prognostic significance. (eurekamag.com)
Metastatic disease is treated in the appropriate situation (such as for a patient with a good performance status and a readily resectable primary tumor) with cytoreductive nephrectomy [ Figure 1 ] and then systemic therapy [ Figure 2 ]," stated Dr. Jonasch. (jnccn.org)
Yervoy helps activate and proliferate T cells, while Opdivo helps existing T cells discover the tumor. (bms.com)
Forty-seven patients with pathologically confirmed metastatic disease underwent GKS to the postoperative resection cavity following gross-total resection of the tumor. (thejns.org)
The radiographic end point was defined as tumor growth control (no tumor growth regarding the resection cavity, and stable or decreasing tumor size for the other metastatic targets). (thejns.org)
Patients who showed good systemic control of their primary tumor tended to have longer survival durations than those who did not (p = 0.004). (thejns.org)
Treatment decisions are based on histopathological staging of the primary tumor, considering depth of tumor infiltration and metastatic spread to lymph nodes or distant organs. (biomedcentral.com)
Surprisingly, most of the genes that were found to be informative for patients' metastasis were related to the immune system but not to common tumor cell characteristics such as angiogenesis, adhesion or invasion. (biomedcentral.com)
Evaluation of radiomics and machine learning in identification of aggressive tumor features in renal cell carcinoma (RCC). (cdc.gov)
Renal cell carcinoma is a unique and challenging tumor because of the frequent occurrence of paraneoplastic syndromes, including hypercalcemia, erythrocytosis, and nonmetastatic hepatic dysfunction (ie, Stauffer syndrome). (medscape.com)
Resolution of symptoms or biochemical abnormalities may follow successful treatment of the primary tumor or metastatic foci. (medscape.com)
Symptoms usually do not appear until late, when the tumor may already be large and metastatic. (msdmanuals.com)

At the Genitourinary Cancers Symposium in Orlando, FL, Dr. Amin described long-term survival in 21 patients with intermediate- or poor-risk metastatic RCC who were treated with autologous dendritic cell immunotherapy in combination with sunitinib. (urologytimes.com)
In this way, it complements sunitinib-induced suppression of regulatory T cells and myeloid-derived suppressor cells. (urologytimes.com)
Only about 13% of sunitinib-treated, unfavorable-risk metastatic RCC patients survive longer than 30 months. (urologytimes.com)
Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. (urotoday.com)
Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib were included. (urotoday.com)
After a median follow-up of 25.2 months, the 18-month survival rate was 77 percent for the immunotherapy combination arm compared with 60 percent for the sunitinib arm. (aacr.org)
In consequence, actual treatment guidelines ( 12 ) recommend a targeted first-line therapy with VEGFR-inhibitors, like sunitinib ( 9 ), pazopanib ( 10 ), or bevacizumab plus immune stimulative IFN, for patients with advanced or metastatic RCC with low to intermediate risk [per Motzer- or MSKCC-Score ( 13 ) /IDMC score International Metastatic Database Consortium (IMDC) adverse risk factors] ( 8 ). (iiarjournals.org)
In the phase III ECOG-ACRIN E2805 trial reported in The Lancet by Naomi B. Haas, MD , of Abramson Cancer Center, University of Pennsylvania, and colleagues, no benefit of adjuvant vascular endothelial growth factor receptor (VEGFR) inhibitor treatment with sunitinib or sorafenib (Nexavar) was observed vs placebo in patients with completely resected high-risk nonmetastatic renal cell -carcinoma. (ascopost.com)
The primary analysis showed no significant differences in disease-free survival, with a median duration of 5.8 years (interquartile range [IQR] = 1.6-8.2 years) for sunitinib (hazard ratio [HR] = 1.02, P = .8038, vs placebo), 6.1 years (IQR = 1.7 years to not estimable) for sorafenib (HR = 0.97, P = .7184, vs placebo), and 6.6 years (IQR = 1.5 years to not estimable) for placebo. (ascopost.com)
Among patients with clear cell histology (approximately 80% across the groups), no differences in disease-free survival were observed with sunitinib (HR = 1.02, P = .8931) or sorafenib (HR = 0.99, P = .8734) vs placebo. (ascopost.com)
Neither sunitinib nor sorafenib improved disease-free survival vs placebo in patients with completely resected high-risk nonmetastatic renal cell carcinoma. (ascopost.com)
Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase III study. (ascopost.com)
ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib. (news-medical.net)
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial. (news-medical.net)
Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. (bmj.com)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. (urotoday.com)
The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. (urotoday.com)
The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma. (urotoday.com)
Supporting phase III data behind the use of sunitinib in patients with metastatic RCC come from Motzer et al. (jnccn.org)

The ongoing phase III ADAPT (The Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma) study is using this approach to personalized immunotherapy, with the goal of randomizing 450 patients. (urologytimes.com)
Based on recently emerged data on efficacy of cancer immunotherapy , we hypothesized that the survival benefit with HDIL-2 extends beyond those achieving objective responses, i.e., to those who achieve stable disease as the best response to treatment . (bvsalud.org)
Immunotherapy and targeted therapy have improved the outlook for metastatic RCC. (wikipedia.org)
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form of kidney cancer . (aacr.org)
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (news-medical.net)
Surgical resection has been the treatment of choice because of superior patient survival compared with traditional immunotherapy. (scirp.org)
With these results from CheckMate -9LA, we now have evidence that this dual immunotherapy combination, when administered concomitantly with two cycles of chemotherapy, provides a survival benefit in this setting - a benefit that was observed early and sustained at one year of follow-up across key subgroups of patients. (bms.com)

The tumour arises from the cells of the proximal renal tubular epithelium. (wikipedia.org)
The tissue of origin for renal cell carcinoma (RCC) is the proximal renal tubular epithelium. (medscape.com)
The proximal renal tubular epithelium is the kidney tissue from which RCC emerges. (alliedacademies.org)

Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web siteJanzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. (indexindex.com)
9 Options for treating localized renal cell carcinoma include nephrectomy (open or laparoscopic, total or partial), laparoscopic and percutaneous ablation (for example, radiofrequency ablation, cryotherapy), and minimally invasive catheter techniques such as superselective chemoembolization. (diagnosticimaging.com)
For stage I renal cell malignant growth estimating under 7 centimeters and restricted to the kidney, nephrectomy or halfway nephrectomy is the treatment of decision and is generally corrective. (alliedacademies.org)
For stage II renal cell malignant growth, laparoscopic extremist nephrectomy is the treatment of decision. (alliedacademies.org)
For stage III renal cell malignant growth, open extremist nephrectomy is the norm of care. (alliedacademies.org)
13 Inclusion criteria comprised patients with a clear-cell component and met criteria for a high risk of recurrence (pT2 with nuclear grade 4 or sarcomatoid differentiation, pT3+, pTanyN+, or M1 NED post completely resected metastatic disease within 1 year of nephrectomy). (onclive.com)
Of 1,087 patients who underwent nephrectomy 27 were identified with direct adrenal involvement and 187 were identified with perinephric fat or renal sinus involvement. (nih.gov)
Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy. (cdc.gov)
ESMO 2022 Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability. (medscape.com)

Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. (medscape.com)
Renal cell carcinomas (RCCs), which originate within the renal cortex, are responsible for 80% to 85% of all primary renal neoplasms. (alliedacademies.org)
24 months in disease-free patients) were reviewed retrospectively from 1399 patients surgically treated for renal neoplasms between 1983 and 2005. (univr.it)
Pulmonary carcinoids are well differentiated low to intermediate grade lung neuroendocrine tumours (LNETs), that belong to the group of lung neuroendocrine neoplasms which also include highly aggressive lung neuroendocrine carcinomas (LNECs). (who.int)

although it is derived from cells of the renal tubular epithelium, it has several histological subtypes which differ in their clinical outcome and biological features. (hindawi.com)

Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry. (moffitt.org)
Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. (medscape.com)

Up to 75% of RCCs are diagnosed in organ-confined stages (T1 and T2), whereas one fourth is already locally advanced or presenting as metastatic disease having a poor prognosis ( 1 ). (iiarjournals.org)
Although patients with Robson stage IIIB renal carcinoma have greatly decreased survival rates, the prognosis for patients with stage Robson IIIA renal carcinoma is not markedly different from that for patients with Robson stage I or II renal carcinoma. (medscape.com)
Although pulmonary carcinoids show relatively good prognosis in comparison to carcinomas, metastatic disease and relapse do occur. (who.int)

Eur Urol, EAU-EBU update series 5:26-37 Google Scholar Saitoh H (1981) Distant metastasis of renal adenocarcinoma. (indexindex.com)
This study aimed at the identification of prognostic gene expression markers in early primary colorectal carcinomas without metastasis at the time point of surgery by analyzing genome-wide gene expression profiles using oligonucleotide microarrays. (biomedcentral.com)
Using machine learning to predict lymph node metastasis in patients with renal cell carcinoma: A population-based study. (cdc.gov)
A clinical prediction model for predicting the risk of liver metastasis from renal cell carcinoma based on machine learning. (cdc.gov)

These investigators examined hereditary predisposition syndromes related to the co-occurrence of melanoma and/or mesothelioma with renal cell carcinoma and their germline associations with BAP1, FLCN, and MITF p.E318K alterations. (medpagetoday.com)
As discussed on this blog , they were approved in combination for treating certain patients with metastatic melanoma in September 2015. (aacr.org)
Since its initial approval in 2014 for metastatic melanoma, Opdivo has added numerous indications across a variety of settings for patients with lung cancer, renal cell carcinoma, Hodgkin lymphoma and continued indications in combination with Yervoy (ipilimumab) for melanoma. (curetoday.com)

4 This may be reflective of the stable rates of patients presenting with advanced and metastatic cancer, a changing biology of kidney cancer, or the overtreatment of indolent lesions with resultant complications of that treatment. (ahrq.gov)
All solid renal masses and cystic lesions with solid components are suspicious for renal cell carcinoma. (ahrq.gov)
MSCT usage is also redefining diagnostic workup of renal lesions and facilitating renal cell cancer staging. (diagnosticimaging.com)
Differentiation of benign from malignant solid renal lesions using CT-based radiomics and machine learning: comparison with radiologist interpretation. (cdc.gov)

Renal cell carcinoma (RCC) is originated from the epithelium of renal tubules. (biomedcentral.com)

Cancer 48:1487-1491Article CAS PubMed Google Scholar Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. (indexindex.com)
Eur Urol 48:77-81 discussion-2Article PubMed Google Scholar Piltz S, Meimarakis G, Wichmann M et al (2003) Surgical treatment of pulmonary metastases from renal cancer. (indexindex.com)
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. (wikipedia.org)
Where the cancer has not metastasised (spread to other organs) or burrowed deeper into the tissues of the kidney, the five-year survival rate is 65-90%, but this is lowered considerably when the cancer has spread. (wikipedia.org)
Renal cell carcinoma (see the image below) is the most common type of kidney cancer in adults. (medscape.com)
Renal cancer occurs in a sporadic (nonhereditary) and a hereditary form, and both forms are associated with structural alterations of the short arm of chromosome 3 (3p). (medscape.com)
Ipilimumab and nivolumab work by releasing two different brakes on natural cancer-fighting cells of the immune system, CTLA4 and PD1, respectively. (aacr.org)
Dr. Spiess' research interests include novel therapies for advanced renal, bladder and penile cancer. (moffitt.org)
Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care? (moffitt.org)
An aberrant miRNA expression could contribute to cancer development and progression [ 6 , 7 ] and could affect their target genes that are involved in many biological processes, such as cell differentiation, proliferation, apoptosis, metabolism, and development [ 8 ]. (hindawi.com)
Targeted therapy uses drugs to hone in on and inhibit proteins that are found on or inside cancer cells. (healthline.com)
Survival was assessed in the overall cohort and in subgroups divided by clinicopathologic characteristics, including the extent of sarcomatoid features, Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria, Heng criteria, and the nature of systemic therapy rendered. (simulations-plus.com)
Renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) are the two most common types of kidney cancer. (ahrq.gov)
In a recent study under review at the Scientific Reports journal and currently posted to the Research Square* preprint server, researchers synthesized and evaluated the antitumoral (against several cancer cell lines) and antiviral [against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] properties of 3-spiro-indolin-2-ones. (news-medical.net)
K. Chiu, A. Razack and A. Maraveyas, "Targeted Therapy in the Management of Elderly Patients with Pancreatic Metastases from Renal Cell Carcinoma," Journal of Cancer Therapy , Vol. 4 No. 9B, 2013, pp. 15-21. (scirp.org)
Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine versus Vinblastine Alone in Patients with Advanced Renal Cell Cancer," Journal of Clinical Oncology, Vol. 17, No. 9, 1999, pp. 2859-2867. (scirp.org)
R. I. Fisher, S. A. Rosenberg and G. Fyfe, "Long-Term Survival Update for High-Dose Recombinant Interleukin-2 in Patients with Renal Cell Carcinoma," The Cancer Journal From Scientific American, Vol. 6, Suppl. (scirp.org)
Medullary renal carcinoma is a rare but aggressive form of renal cell cancer that seen in sickle cell disease. (alliedacademies.org)
However, most data about use of nivolumab and ipilimumab (nivo-ipi) in kidney cancer comes from one trial in clear cell RCC (ccRCC). (bmj.com)
In the ongoing, randomised, open-label, phase 3 KEYNOTE-426 study, adults (≥18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enrolled in 129 sites (hospitals and cancer centres) across 16 countries. (urotoday.com)
1 Renal cell carcinoma (RCC) is the most common malignancy of the kidney and globally accounts for approximately 2% of cancer diagnoses and deaths. (onclive.com)
A recent study found that Opdivo improves survival in patients with gastric or gastroesophageal junction (GEJ) cancer. (curetoday.com)
ONO-4538-12 is the first randomized, phase 3 Immuno-Oncology trial to demonstrate improved survival for patients with previously treated advanced or recurrent gastric cancer,' Ian M. Waxman, M.D., development lead, Gastrointestinal Oncology, Bristol-Myers Squibb, said in a statement. (curetoday.com)
Median survival for patients with pT3a disease and perinephric or renal sinus fat involvement was 36 months with a 36% 5-year cancer specific survival rate. (nih.gov)
It has been an exciting 15 years for renal cell carcinoma," noted Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Director of the Von Hippel-Lindau Clinical Center at The University of Texas MD Anderson Cancer Center. (jnccn.org)
Cancer Progenitor Cells: The Result of an Epigenetic Event? (iiarjournals.org)
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect? (iiarjournals.org)
PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced the first presentation of results from the Phase 3 CheckMate -9LA trial, which demonstrated a statistically significant and clinically meaningful survival benefit with Opdivo (nivolumab) plus Yervoy (ipilimumab), given concomitantly with two cycles of chemotherapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). (bms.com)
The nivolumab plus ipilimumab combination has been shown to increase survival in patients with first-line non-small cell lung cancer, and adding a limited course of chemotherapy may help mitigate the risk of early disease progression," said Martin Reck, M.D., Ph.D., CheckMate -9LA study investigator, Lung Clinic Grosshansdorf, German Center of Lung Research. (bms.com)
Understanding that each patient facing a diagnosis of metastatic non-small lung cancer is unique, we've approached our development program with the goal of delivering a number of potentially durable solutions for the significant number of first-line patients who still need new options," said Nick Botwood, M.D., vice president, Oncology Clinical Development, Bristol Myers Squibb. (bms.com)
Despite a high incidence of adverse events, adding aflibercept to FOLFIRI chemotherapy is associated with "a consistent trend" of increased survival among metastatic colorectal cancer patients, regardless of patients' previous bevacizumab treatment status, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting. (cancertherapyadvisor.com)
Regorafenib prolongs PFS and OS in metastatic colorectal cancer that has progressed after all approved standard therapies, according to the phase 3 CORRECT trial presented at the 2012 American Society of Clinical Oncology Annual Meeting. (cancertherapyadvisor.com)
The experimental agent trastuzumab emtansine (T-DM1) offers significant and "clinically meaningful" improvement in PFS in some patients with HER2+locally advanced or metastatic breast cancer, according to a phase 3 study prestented at the 2012 American Society of Clinical Oncology Annual Meeting. (cancertherapyadvisor.com)
Thus, our data emphasize that the proper function of a comprehensive network of immune response genes is of vital importance for the survival of colorectal cancer patients. (biomedcentral.com)
Renal cell carcinoma (RCC) is the most common renal cancer. (msdmanuals.com)
'Unprecedented' 3-Year Sustained Survival in SCLC With New Combo The combination of durvalumab plus etoposide and cisplatin/carboplatin should now become the standard of care for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). (medscape.com)
Androgen Deprivation Alone No Longer Acceptable for mCSPC Androgen deprivation alone is no longer an acceptable option for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), experts contend. (medscape.com)

Targeted therapeutic agents for treating metastatic RCC has not led to an improved survival. (renalandurologynews.com)
A study published recently in Urologia Internationalis (online ahead of print) found that the advent of targeted therapeutic agents for treating metastatic renal cell carcinoma (RCC) -which began with the FDA approval of sorafenib in 2005-has not led to an improvement in survival rates. (renalandurologynews.com)
Urol Clin North Am 30:843-852Article PubMed Google Scholar Staehler M, Haseke N, Schöppler G et al (2007) Modern therapeutic approaches in metastatic renal cell carcinoma. (indexindex.com)
Context While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. (lu.se)

Patients are in need of new treatments that can improve survival outcomes, and these positive results support the potential of KEYTRUDA in combination with chemotherapy as a first-line treatment for patients with the most common form of malignant mesothelioma. (merck.com)
Induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck did not improve OS, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting. (cancertherapyadvisor.com)
as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)

Adding surgery and/or radiation to systemic therapy (multimodal therapy) improved clinical outcomes in patients with renal cell carcinoma (RCC) with brain metastases, reports a university-based research team. (medpagetoday.com)
Commentary on "Conditional survival of patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A population-based study. (elsevierpure.com)
Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC). (urotoday.com)
Targeted therapy and immunomodulatory agents are considered standard of care in patients with metastatic disease. (medscape.com)
The U.S.-based, multicenter, investigator-initiated trial enrolled 83 patients with metastatic renal cell carcinoma (96% clear cell histology, 51% treatment-naive) who had received no prior checkpoint inhibitor therapy between October 2017 and July 2019. (ascopost.com)
In recent years, the advent of targeted therapy has transformed the outcomes of patients with metastatic RCC although little evidence is available on its effectiveness on this subset of patients. (scirp.org)
The accompanying elements increment an individual's gamble for renal malignant growth: more established age, stoutness, hypertension, persistent renal disappointment, dialysis therapy, polycystic kidney illness, African American race, sickle cell infection, and renal stones [ 1 ]. (alliedacademies.org)

4 Seventy-five percent of patients have clear cell histology (ccRCC), 10% to 15% have papillary, 5% have chromophobe histology, and the additional patients have even more rare subtypes such as translocation or renal medullary carcinoma. (onclive.com)
Deep learning can predict survival directly from histology in clear cell renal cell carcinoma. (cdc.gov)

Surgical resection remains the only known curative treatment for localized renal cell carcinoma, and it is also used improve outcome or for palliation in metastatic disease. (medscape.com)
In recent years, multiple agents have been developed for systemic treatment of metastatic disease. (medscape.com)
the five-year relative survival rate for this form of the disease is just 11.6 percent. (aacr.org)
for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 12 percent, with no identified cure for the disease. (businesswire.com)
Treatment protocols for renal cell carcinoma are provided below, including treatment of localized and advanced disease and recommendations for patients with predominantly clear cell carcinoma and those with predominantly non-clear cell carcinoma. (medscape.com)
The primary objective was to compare disease-free survival between each experimental group and placebo in the intention-to-treat population. (ascopost.com)
Families at high risk for creating renal disease were considered, which prompted the cloning of qualities. (alliedacademies.org)
Five-year survival is dependent on stage at diagnosis: 93% for stage I, 72.5% for stage II/III, and 12% for stage IV metastatic disease. (onclive.com)
Results showed that disease-free survival (DFS) was significantly longer in patients who received pembrolizumab, with 24-month DFS rates at 77.3% with pembrolizumab vs 68.1% with placebo (HR, 0.68, P = .002). (onclive.com)
The records of 24 patients with renal cell carcinoma involving the inferior vena cava who were free of metastatic disease at presentation were reviewed retrospectively. (eurekamag.com)
When the group was analyzed according to the level of extension of the vena caval thrombus marked differences in the rate of survival and of incidence of local progression of disease were found. (eurekamag.com)
0.001), which was similar to median survival of those with stage pT4 disease (11 months). (nih.gov)
Approximately 30% of patients with renal carcinoma (RCC) present with metastatic disease. (medscape.com)

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. (nih.gov)
0.001) recurrences, whereas there was no correlation of recurrences in the operated kidney (P = 0.372) or contralateral kidney (P = 0.898).CONCLUSIONS The prognostic accuracy and applicability of the UISS for distant and local recurrences is confirmed, whereas renal relapses have an independent course. (univr.it)
Incremental value of radiomics with machine learning to the existing prognostic models for predicting outcome in renal cell carcinoma. (cdc.gov)
A comprehensive texture feature analysis framework of renal cell carcinoma: pathological, prognostic, and genomic evaluation based on CT images. (cdc.gov)

Renal cell carcinoma accounts for about 90 percent of kidney cancers. (aacr.org)
4 While renal cell carcinoma only represents 2% of adult cancers, it is among the most lethal, with approximately 35% of patients dying within 5 years of diagnosis. (ahrq.gov)
Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year. (onclive.com)

Imaging observation is a choice in older patients with a short future who are bad careful up-and-comers, as numerous renal cell malignant growths are slow developing. (alliedacademies.org)
Stage IV renal cell malignant growth isn't treatable. (alliedacademies.org)

Specifically, the FDA approved a combination of ipilimumab (Yervoy) and nivolumab (Opdivo) for the treatment of intermediate- or poor-risk, previously untreated advanced renal cell carcinoma. (aacr.org)
The approval of the ipilimumab and nivolumab combination for intermediate- or poor-risk, previously untreated advanced renal cell carcinoma was based on results from the CheckMate 214 phase III clinical trial, which were published recently in The New England Journal of Medicine . (aacr.org)
In the phase II OMNIVORE study reported in the Journal of Clinical Oncology , Rana R. McKay, MD , and colleagues did not find evidence supporting a strategy of discontinuing nivolumab monotherapy in responders and adding ipilimumab in nivolumab nonresponders among patients with metastatic renal cell carcinoma. (ascopost.com)
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carnioma: results from the phase 3b/4 CheckMate 920 trial. (bmj.com)

Eligible patients were required to have locally advanced or metastatic clear-cell RCC, ECOG performance status 0-2, and had to be intermediate or poor risk per the IMDC criteria (Heng, JCO, 2009). (businesswire.com)
1, 19-21 In addition, all current standard imaging modalities (CT, magnetic resonance imaging (MRI) and ultrasound) are able to provide insight into whether renal masses are localized or locally advanced, thus suggesting pathologic aggressiveness. (ahrq.gov)

The pancreas is an uncommon but recognizable site for metastases from renal cell carcinoma (RCC). (scirp.org)

risk of esophageal squamous cell carcinoma. (who.int)
PMID:18786442 mutations and the risk of esophageal squamous cell carcinoma. (who.int)
Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch squamous cell carcinoma in a high-risk region in Iran. (who.int)

Objective To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC. (lu.se)
Conclusions This systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. (lu.se)

Other less common subtypes are clear cell, papillary, and chromophobe malignancies. (alliedacademies.org)
The accompanying innate infections increment the gamble of RCC: tuberous sclerosis, Von Hippel-Lindau condition Birt- Hogg-Dube disorder, genetic papillary renal carcinoma, and inherited leiomyomatosis and renal cell carcinoma (HLRCC). (alliedacademies.org)

Best responses on treatment were associated with survival outcomes using log-rank and COX regression with a landmark analysis at 2 months. (bvsalud.org)

Automated classification of solid renal masses on contrast-enhanced computed tomography images using convolutional neural network with decision fusion. (cdc.gov)

Experimental treatment approaches include vaccines and nonmyeloablative allogeneic peripheral blood stem cell transplantation. (medscape.com)
Darmstadt, Germany and New York, US, May 14, 2019 - Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). (pfizer.com)
Background/Aim: The combination of bevacizumab (BEV) plus interferon alpha-2a (IFN) constitutes an option for first-line treatment of metastatic renal cell carcinoma. (iiarjournals.org)
Ipsen remains on track to submit the regulatory dossier for cabozantinib as a treatment for first-line advanced renal cell carcinoma in Europe in the third quarter of 2017. (businesswire.com)
These results continue to support the first-line treatment with pembrolizumab plus axitinib as the standard of care of advanced renal cell carcinoma. (urotoday.com)
Antiangiogenic therapies remain the standard of care in the front-line setting for renal cell carcinoma, although vascular endothelial growth factor (VEGF) blockade is not sufficient, and many patients do not respond to such treatment. (jnccn.org)
Axitinib is effective in the first-line treatment of metastatic renal cell carcinoma, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting. (cancertherapyadvisor.com)
Exclusion criteria were: presence of a secondary carcinoma, patient age less than 40 years at the time of surgery, local recurrence, preoperative treatment and radiotherapy. (biomedcentral.com)
The frequency of treatment will initially be once a week for 3 weeks and then biweekly or monthly until 24 months, depending on the response of myeloid suppressor cells (MDSC) on days 21 and 28. (who.int)

Go to Clear Cell Renal Cell Carcinoma and Sarcomatoid and Rhabdoid Renal Cell Carcinoma for complete information on these topics. (medscape.com)

In particular, recurrence sites were categorized into local, renal (ipsilateral or contralateral) and distant (single-site or disseminated).RESULTS The records were reviewed of 814 patients with a mean follow-up of 75.6 months. (univr.it)

One prediction model developed by the International Metastatic Renal-Cell Carcinoma Database Consortium classifies patients based on the presence or absence of six risk factors. (aacr.org)
Randomisation was done using an interactive voice response system or integrated web response system, and was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and geographical region. (urotoday.com)

During his presentation at the NCCN 20th Annual Conference, Dr. Jonasch focused on the host of systemic therapies now available for metastatic renal cell carcinoma (RCC) that have category 1 evidence in the most recent version of the NCCN Guidelines. (jnccn.org)

1-4 Low-dose excretory phase scans enable assessment of the renal pelvis and ureters. (diagnosticimaging.com)
This is an elegant method of limiting radiation dose, although it decreases contrast between renal arteries, parenchyma, and renal pelvis when compared with multiphasic imaging. (diagnosticimaging.com)

Increasing use of ultrasound and MSCT for clinical diagnoses has led to an increase in the detection of renal masses. (diagnosticimaging.com)
Phase III Trial of Interferon Alfa-2a with or without 13-Cis-Retinoic Acid for Patients with Advanced Renal Cell Carcinoma," Journal of Clinical Oncology, Vol. 18, No. 16, 2000, pp. 2972-2980. (scirp.org)
Randomized Phase III Trial of High-Dose Interleukin-2 versus Subcutaneous Interleukin-2 and Interferon in Patients with Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, Vol. 23, No. 1, 2005, pp. 133-141. (scirp.org)
Clinical end points were defined as functional status (assessed prospectively using the Karnofsky Performance Scale) and survival. (thejns.org)

Background Non-clear cell renal cell carcinoma (nccRCC) represents around 25% of RCC variants. (bmj.com)

among these, about 80% are clear cell renal carcinomas histologically ( 2 ). (iiarjournals.org)
All 6 patients had a primary RCC of clear cell type. (scirp.org)
Differentiation of clear cell and non-clear-cell renal cell carcinoma through CT-based Radiomics models and nomogram. (cdc.gov)
A CT-based deep learning model for predicting the nuclear grade of clear cell renal cell carcinoma. (cdc.gov)
MRI Radiomics for the Prediction of Fuhrman Grade in Clear Cell Renal Cell Carcinoma: a Machine Learning Exploratory Study. (cdc.gov)

Anatomy5

Organisms1

Diseases39

Chemicals and Drugs35

Analytical, Diagnostic and Therapeutic Techniques and Equipment44

Psychiatry and Psychology1

Phenomena and Processes11

Disciplines and Occupations1

Anthropology, Education, Sociology and Social Phenomena1

Information Science1

Named Groups1

Health Care19

Geographicals1

Overall survival33

Progression-free sur14

MRCC9

Tumors13

Tumor26

Sunitinib19

Immunotherapy7

Proximal renal tubular epithelium3

Nephrectomy9

Neoplasms4

Tubular epithelium1

Urothelial Carcinoma2

Prognosis3

Metastasis4

Melanoma3

Lesions4

Epithelium1

Cancer37

Therapeutic4

Chemotherapy3

Therapy7

Histology2

Disease13

Prognostic4

Cancers3

Malignant2

Ipilimumab4

Locally advanced2

Metastases from renal1

Squamous Cell Carc3

CcRCC2

Papillary2

Outcomes1

Solid renal masses1

Treatment9

Sarcomatoid1

Recurrence1

Database Consortium2

Therapies1

Pelvis2

Clinical4

Represents1

Clear-cell5